Comparing LadRx (OTCMKTS:CYTR) & Inhibrx (NASDAQ:INBX)
Comparing LadRx (OTCMKTS:CYTR) & Inhibrx (NASDAQ:INBX)
LadRx (OTCMKTS:CYTR – Get Rating) and Inhibrx (NASDAQ:INBX – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.
LadRx（OTCMKTS: CYTR — 获取评级）和 Inhibrx（纳斯达克股票代码：INBX — 获取评级）都是小型医疗公司，但哪家企业更好？我们将根据两家企业的机构所有权、股息、分析师建议、盈利能力、收益、估值和风险对比这两家企业。
Institutional & Insider Ownership
机构和内部所有权
0.1% of LadRx shares are held by institutional investors. Comparatively, 72.8% of Inhibrx shares are held by institutional investors. 12.8% of LadRx shares are held by company insiders. Comparatively, 25.8% of Inhibrx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
0.1% 的LadRx股票由机构投资者持有。相比之下，72.8％的Inhibrx股票由机构投资者持有。12.8％的LadRx股票由公司内部人士持有。相比之下，Inhibrx的股票中有25.8％由公司内部人士持有。强大的机构所有权表明大型基金经理、对冲基金和捐赠基金认为一家公司有望实现长期增长。
Profitability
盈利能力
This table compares LadRx and Inhibrx's net margins, return on equity and return on assets.
该表比较了LadRx和Inhibrx的净利润率、净资产回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| LadRx | N/A | -67.61% | -45.39% |
| Inhibrx | -6,625.27% | -1,278.54% | -71.71% |
| 净利润 | 股本回报率 | 资产回报率 | |
| LadRx | 不适用 | -67.61% | -45.39% |
| Inhibrx | -6,625.27% | -1,278.54% | -71.71% |
Analyst Recommendations
分析师建议
This is a summary of current ratings for LadRx and Inhibrx, as provided by MarketBeat.com.
这是Marketbeat.com提供的LadRx和Inhibrx当前收视率的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| LadRx | 0 | 0 | 0 | 0 | N/A |
| Inhibrx | 0 | 0 | 3 | 0 | 3.00 |
| 卖出评级 | 持有评级 | 买入评级 | 强劲的买入评级 | 评分分数 | |
| LadRx | 0 | 0 | 0 | 0 | 不适用 |
| Inhibrx | 0 | 0 | 3 | 0 | 3.00 |
Inhibrx has a consensus target price of $47.00, suggesting a potential upside of 117.90%. Given Inhibrx's higher possible upside, analysts clearly believe Inhibrx is more favorable than LadRx.
Inhibrx的共识目标价格为47.00美元，表明潜在的上涨空间为117.90％。鉴于Inhibrx可能有更高的上行空间，分析师显然认为Inhibrx比LadRx更有利。
Volatility & Risk
波动性与风险
LadRx has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500. Comparatively, Inhibrx has a beta of 2.96, suggesting that its share price is 196% more volatile than the S&P 500.
LadRx的beta值为1.96，这表明其股价的波动性比标准普尔500指数高96％。相比之下，Inhibrx的beta值为2.96，这表明其股价的波动性比标准普尔500指数高196％。
Earnings and Valuation
收益和估值
This table compares LadRx and Inhibrx's revenue, earnings per share and valuation.
该表比较了LadRx和Inhibrx的收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| LadRx | N/A | N/A | -$6.70 million | ($0.15) | -0.61 |
| Inhibrx | $2.19 million | 429.13 | -$145.23 million | ($3.62) | -5.96 |
| 总收入 | 价格/销售比率 | 净收入 | 每股收益 | 市盈率 | |
| LadRx | 不适用 | 不适用 | -670 万美元 | (0.15 美元) | -0.61 |
| Inhibrx | 219 万美元 | 429.13 | -1.4523 亿美元 | (3.62 美元) | -5.96 |
LadRx has higher earnings, but lower revenue than Inhibrx. Inhibrx is trading at a lower price-to-earnings ratio than LadRx, indicating that it is currently the more affordable of the two stocks.
与Inhibrx相比，LadrX的收益更高，但收入更低。Inhibrx的市盈率低于LadRx，这表明它是目前两只股票中更实惠的一只。
About LadRx
关于 LadRx
(Get Rating)
（获取评级）
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
LadRx Corporation是一家生物制药公司，从事治疗癌症患者的疗法的发现和开发。该公司的先进药物偶联物阿多柔比星正在进行后期临床试验，是抗癌药物多柔比星的一种版本。其临床前疗法包括针对癌症的链接活化药物释放的7、8、9和10。该公司前身为CytrX Corporation，并于2022年9月更名为LadrX Corporation。LadRx Corporation 成立于 1985 年，总部位于加利福尼亚州洛杉矶。
About Inhibrx
关于 Inhibrx
(Get Rating)
（获取评级）
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Inhibrx, Inc. 是一家临床阶段的生物技术公司，专注于开发一系列新的生物制剂候选药物。该公司的候选治疗药物包括 INBRX-109，一种死亡受体 5 的四价激动剂，正在进行治疗软骨肉瘤、间皮瘤和胰腺腺癌等癌症的 2 期临床试验；INBRX-105，一种程序性死亡配体 1 的四价条件激动剂和 4-1BB 的条件激动剂，正在进行治疗局部晚期或转移性实体瘤患者的第 1 期临床试验；以及 INBRX-101，一种 alpha-1 抗胰蛋白酶 (AAT)-Fc 融合蛋白候选药物，正处于 1 期临床试验治疗AAT缺乏症患者。它还提供 INBRX-106，一种 OX40 的六价激动剂，用于一系列肿瘤适应症。该公司成立于2010年，总部位于加利福尼亚州拉霍亚。
Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收 LadRx 的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收LadrX及相关公司的最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。